<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01954992</url>
  </required_header>
  <id_info>
    <org_study_id>EP-GF-301</org_study_id>
    <nct_id>NCT01954992</nct_id>
  </id_info>
  <brief_title>Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eleison Pharmaceuticals LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eleison Pharmaceuticals LLC.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to assess whether glufosfamide provides additional survival benefit as
      compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already
      progressed or failed therapy on a gemcitabine based first line regimen.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Approximately 3-6 months</time_frame>
    <description>Time from Randomization to death from any cause</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Metastatic Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>glufosfamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glufosfamide: 4500 mg/m2 IV over 6 hours on Day 1 of each 21-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-FU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glufosfamide</intervention_name>
    <description>Glufosfamide: 4500 mg/m2 IV over 6 hours (¼ dose over 30 minutes, ¾ dose over remaining 5.5 hours) on Day 1 of each 21-day cycle.</description>
    <arm_group_label>glufosfamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week</description>
    <arm_group_label>5-FU</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Pancreatic adenocarcinoma proven either by histology (surgical biopsy) or cytology
             (CT- or endoscopic-guided)

          -  Metastatic pancreatic cancer

          -  Disease progression during or after treatment with gemcitabine (alone or in
             combination with other agents; at regular, not radiosensitizing, doses)

          -  Measurable or nonmeasurable disease by RECIST criteria (at least one target or
             nontarget lesion)

          -  Recovered from reversible toxicities of prior therapy

          -  ECOG performance status 0-1

          -  All women of childbearing potential and all men must agree to use effective means of
             contraception (surgical sterilization or the use of barrier contraception with either
             a condom or diaphragm in conjunction with spermicidal gel or an IUD) from entry into
             the study through 6 months after the last dose of chemotherapy

          -  Ability to understand the purposes and risks of the study and has signed a written
             informed consent form approved by the investigator's IRB/Ethics Committee

        Exclusion Criteria:

          -  More than one prior systemic therapy regimen for metastatic pancreatic cancer
             (radiosensitizing doses of 5-FU or gemcitabine at the time of initial radiotherapy do
             not count as a prior systemic therapy regimen)

          -  Hormonal therapy, radiation therapy, biologic therapy, chemotherapy or other systemic
             antitumor therapy for pancreatic cancer within 14 days prior to Cycle 1 Day 1

          -  Insulin-dependent diabetes mellitus (patients with type 2 diabetes controlled with
             oral glucose lowering agents and the occasional use of insulin are permitted in the
             study)

          -  Symptomatic brain metastases (baseline CT scan is not required in asymptomatic
             patients)

          -  Active clinically significant infection requiring antibiotics

          -  Known HIV positive or active hepatitis B or C

          -  Recent (one year) history or symptoms of cardiovascular disease (NYHA Class 2, 3, or
             4), particularly coronary artery disease, arrhythmias or conduction defects with risk
             of cardiovascular instability, uncontrolled hypertension, clinically significant
             pericardial effusion, or congestive heart failure

          -  No other active malignancies (other than treated non-melanoma skin cancer or treated
             in situ cancer) within the past year

          -  Major surgery within 3 weeks of the start of study treatment, without complete
             recovery

          -  Clinically significant abnormalities in laboratory test results (including complete
             blood count, chemistry panel including electrolytes, and urinalysis)

               -  Hemoglobin &lt;9 g/dL (may receive transfusion or erythropoietin to maintain)

               -  ANC &lt;1500/μL

               -  Platelet count &lt;100,000/μL

               -  Total bilirubin &gt; 1.5×ULN

               -  AST/ALT &gt; 2.5-fold above ULN (&gt;5-fold above ULN if liver metastases)

               -  Phosphorus &lt; LLN

               -  Potassium &lt; LLN

               -  Serum creatinine &gt; 2 mg/dL

               -  Creatinine clearance &lt; 60 mL/min (calculated by Cockcroft-Gault formula)

          -  Females who are pregnant or breast-feeding

          -  Participation in an investigational drug or device study within 14 days of the first
             day of dosing on this study

          -  Concomitant disease or condition that could interfere with the conduct of the study,
             or that would, in the opinion of the investigator, pose an unacceptable risk to the
             patient in this study

          -  Any medical history, concurrent disease or concomitant medication which could
             reasonably predispose the patient to renal insufficiency while on study treatment

          -  Contraindication or unwillingness to undergo multiple CT scans

          -  Unwillingness or inability to comply with the study protocol for any other reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edwin Thomas</last_name>
    <role>Study Director</role>
    <affiliation>Eleison Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edwin Thomas</last_name>
    <phone>215 554 3530</phone>
    <email>clinical@eleison-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Comprehensive Cancer Care Medical Group, Inc.</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92879</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsa Honorio</last_name>
      <phone>951-276-2760</phone>
      <email>ehonorio@compcareresearch.com</email>
    </contact>
    <investigator>
      <last_name>Rehana Baqai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Compassionate Care Research Group, Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Etheredge</last_name>
      <phone>714-698-0300</phone>
      <phone_ext>206</phone_ext>
      <email>cetheredge@compcareresearch.com</email>
    </contact>
    <investigator>
      <last_name>Haresh S Jhangiani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hao Wei Zhang MD, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eryn Ferdman</last_name>
      <phone>424-208-8866</phone>
      <email>Eryn@TRMLLC.com</email>
    </contact>
    <investigator>
      <last_name>Hao Wei Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Compassionate Cancer Care Medical Group, Inc.</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corina King</last_name>
      <phone>951-276-2760</phone>
      <email>cking@compcareresearch.com</email>
    </contact>
    <investigator>
      <last_name>Brian Choi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research Institute</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Bettino</last_name>
      <phone>562-652-6532</phone>
      <email>kbettino@airesearch.us</email>
    </contact>
    <investigator>
      <last_name>Richy Agajanian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christina Care Health System</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Combs</last_name>
      <phone>302-623-4638</phone>
      <email>kcombs@christinacare.org</email>
    </contact>
    <investigator>
      <last_name>Michael Guarino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lakeland Regional Cancer Center</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Stewart</last_name>
      <phone>863-904-1877</phone>
      <email>robin.stewart@lrmc.com</email>
    </contact>
    <investigator>
      <last_name>Madhavi Venigalla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Rowland</last_name>
      <phone>813-745-1157</phone>
      <email>michael.rowland@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Richard Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Simmons Cancer Institute</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Robinson</last_name>
      <phone>217-545-7969</phone>
      <email>krobinson@siumed.edu</email>
    </contact>
    <investigator>
      <last_name>Meghna Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Investigative Clinical Research of Indiana, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>RHHP/Hope Center</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacquelyn Bradfield</last_name>
      <phone>812-234-0098</phone>
      <email>Jacquelyn.bradfield@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Ashis K Chakrabarti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic Oncology</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheri Gatchel</last_name>
      <phone>515-239-2684</phone>
      <email>gatchel@MGMC.com</email>
    </contact>
    <investigator>
      <last_name>Debra Prow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CBC Group Consulting in Blood Disorders and Cancer, PSC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly O'neill Richey</last_name>
      <phone>502-897-1166</phone>
      <phone_ext>1420</phone_ext>
      <email>kelly.oneillrichey@bhsi.com</email>
    </contact>
    <investigator>
      <last_name>Wanjian Zhong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reliant Medical Group</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcia Kirkpatrick, RN, BSN</last_name>
      <phone>508-556-5429</phone>
      <email>marcia.kirkpatrick@reliantmedicalgroup.org</email>
    </contact>
    <investigator>
      <last_name>Amr Hassan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Kalbouneh</last_name>
      <phone>314-577-8916</phone>
      <email>kalbousl@slu.edu</email>
    </contact>
    <investigator>
      <last_name>Nishant Poddar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Norris Cotton Cancer Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates</name>
      <address>
        <city>Sparta</city>
        <state>New Jersey</state>
        <zip>07871</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Koek, CRC</last_name>
      <phone>585-276-4448</phone>
      <email>laurie_koek@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Marcus Noel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Smith</last_name>
      <phone>330-417-8231</phone>
      <email>csmith@gabrailcancercenter.com</email>
    </contact>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny Singer Research Institute- West Penn</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Hebda</last_name>
      <phone>412-491-1384</phone>
      <email>shebda@wpahs.org</email>
    </contact>
    <investigator>
      <last_name>Moses Raj</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Biomedical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susie Owenby</last_name>
      <phone>865-934-2672</phone>
      <email>sowenby@biomed-research.com</email>
    </contact>
    <investigator>
      <last_name>David R Schumaker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Health Physicians Group</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Carson</last_name>
      <phone>972-755-8076</phone>
      <email>lisacarson@texashealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Lee Knox</last_name>
      <phone>214-570-2334</phone>
      <email>leeknox@texashealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Alfred DiStefano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2013</study_first_submitted>
  <study_first_submitted_qc>September 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2013</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glufosfamide</keyword>
  <keyword>5-FU</keyword>
  <keyword>metastatic pancreatic adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

